| 18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. | |
| | |
MedLine Citation:
|
PMID: 21385914 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the diagnostic performance of (18)F-fludeoxyglucose ((18)F-FDG) positron emission tomography (PET)/CT in patients with suspected large-vessel vasculitis and its potential to evaluate the extent and activity of disease. METHODS: 78 consecutive patients (mean age 63 years; 53 females) with suspected large-vessel vasculitis were evaluated with (18)F-FDG PET/CT.( 18)F-FDG uptake in the aorta and major branches was visually graded using a four-point scale and quantified with standardised uptake values (SUV(max)). According to clinical diagnosis, patients were classified into three groups: (a) steroid-naïve, large-vessel vasculitis (16 patients), (b) vasculitis on steroid treatment (18 patients) and (c) no evidence of vasculitis (44 patients). Analysis of variance and linear regression were used to investigate the association of (18)F-FDG uptake with clinical diagnosis and inflammatory markers. RESULTS: (18)F-FDG PET/CT was positive (visual uptake ≥ 2; equal to or greater than liver) in all patients with steroid-naïve, large-vessel vasculitis. The thoracic aorta, the carotid and the subclavian arteries were most frequently involved. In these patients, SUV(max) values were significantly higher than in the other groups (analysis of variance; p<0.05). Linear regression showed a significant positive association (b-coefficients: 0.018-0.02; p<0.05) between SUV(max) of the thoracic aorta and inflammatory markers in patients with vasculitis (Groups a and b). Patients on steroid treatment showed low visual scores (uptake <2) and significantly lower SUV(max) values than steroid-naïve patients. CONCLUSION: (18)F-FDG PET/CT can detect the extent and activity of large-vessel vasculitis in untreated patients and is unreliable in diagnosing vasculitis in patients on steroids. |
| | |
Authors:
|
N D Papathanasiou; Y Du; L J Menezes; A Almuhaideb; M Shastry; H Beynon; J B Bomanji |
Related Documents
:
|
6291864 - Assessment of activity in sarcoidosis. sensitivity and specificity of 67gallium scintig... 11055654 - Mycobacterium tuberculosis infections after renal transplantation. 19662584 - Sonographic signs of amyloidosis. 136524 - Unsuspected substantial pericardial effusions detected by echocardiography. 22891804 - Atrial fibrillation is associated with severe sleep-disordered breathing in patients wi... 20606434 - Csf-tau and csf-abeta(1-42) in posterior cortical atrophy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-03-08 |
Journal Detail:
|
Title: The British journal of radiology Volume: 85 ISSN: 1748-880X ISO Abbreviation: Br J Radiol Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-06-05 Completed Date: 2012-08-06 Revised Date: 2013-06-05 |
Medline Journal Info:
|
Nlm Unique ID: 0373125 Medline TA: Br J Radiol Country: England |
Other Details:
|
Languages: eng Pagination: e188-94 Citation Subset: AIM; IM |
Affiliation:
|
Institute of Nuclear Medicine, University College Hospital, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Female Fluorodeoxyglucose F18 / diagnostic use* Humans Male Middle Aged Positron-Emission Tomography and Computed Tomography* Radiopharmaceuticals / diagnostic use* Retrospective Studies Vasculitis / blood, radionuclide imaging* |
| Grant Support | |
ID/Acronym/Agency:
|
//Department of Health |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Time-resolved MR angiography for detecting and grading ovarian venous reflux: comparison with conven...
Next Document: Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer:...